Avelumab(Merck KGaA / Pfizer)은 Locally Advanced or Metastatic Urothelia 표적 항체로, Non Small Cell Lung Cancer; Colorectal Cancer 영역에서 개발·상용화 중입니다. 작용기전: , clinical applications, and biomarkers of this treatment approach. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 20% (ClinicalTrials.gov NCT04215146). PK: t½ 6.1 h. 차별점: novel therapeutic strategy for clinical management.
Locally Advanced or Metastatic Urothelia
Non Small Cell Lung Cancer; Colorectal Cancer
Active
oncolytic virus VV1 as monotherapy or in combination with avelumab in
vedotin (EV) was the most common second-line tr
novel therapeutic strategy for clinical management
, clinical applications, and biomarkers of this treatment approach
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
DNA damage, cGAS-STING activation, and enhanced tumor immunogenicity, which may be amplified by PD-1/PD-L1 blockade
biomarkers to predict the risk of UC patients developing irAEs
resistance to standard therapies
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Avelumab(Merck KGaA / Pfizer)은 Locally Advanced or Metastatic Urothelia 표적 항체로, Non Small Cell Lung Cancer; Colorectal Cancer 영역에서 개발·상용화 중입니다. 작용기전: , clinical applications, and biomarkers of this treatment approach. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 20% (ClinicalTrials.gov NCT04215146). PK: t½ 6.1 h. 차별점: novel therapeutic strategy for clinical management.
Locally Advanced or Metastatic Urothelia
Non Small Cell Lung Cancer; Colorectal Cancer
Active
oncolytic virus VV1 as monotherapy or in combination with avelumab in
vedotin (EV) was the most common second-line tr
novel therapeutic strategy for clinical management
, clinical applications, and biomarkers of this treatment approach
immune-mediated myocarditis, autoimmune myocarditis, pericardial effusion, cardiac tamponade, malignant pericarditis, embolism, and thr
DNA damage, cGAS-STING activation, and enhanced tumor immunogenicity, which may be amplified by PD-1/PD-L1 blockade
biomarkers to predict the risk of UC patients developing irAEs
resistance to standard therapies
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.